

Cancer **I**mmunology **I**mmunotherapy

Founding Editor
G. Mathé

Other Biological Response Modifications

Volume 33 1991

Editors in Chief

R. W. Baldwin E. Mihich

Editorial Board

F. Balkwill London
J. Bennett Albany, NY
N. Bloksma Utrecht
H. Blythman Basel
R. Bolhuis Rotterdam
V. S. Byers Nottingham
T. Carey Ann Arbor, MI
M. Cheever Seattle, WA
M. Colnaghi Milan
S. Dray Chicago, IL
S. Eccles Sutton, Surrey
M. J. Ehrke Buffalo, NY
M. Fopp St. Gallen
E. Grimm Houston, TX

K. Hellström Seattle, WA
K. Höffken Essen
A. Houghton New York, NY
H. Kirchner Heidelberg
E. Kleinerman Houston, TX
W. Knapp Vienna
H. Kobayashi Sapporo
M. Mastrangelo Philadelphia, PA
J. McVie London
M. Mitchell Los Angeles, CA
M. Moore London
R. J. North Saranac Lake, NY
G. Parmiani Milan
M. Price Nottingham

R. Rees Sheffield
R. A. Reisfeld La Jolla, CA
H. F. Sewell Nottingham
K. Sikora London
Z. Steplewski Philadelphia, PA
G. Stevenson Southampton
J. Talmadge Omaha, NE
E. Tsubura Osaka
A. Uchida Kyoto
F. Vanky Stockholm
E. Vitetta Dallas, TX
B. Vose Cheshire



Springer International

Cancer Immunology Immunotherapy

Other Biological Response Modifications

This journal was founded in 1976. Founding editor: G. Mathé

Editors: R. W. Baldwin, E. Mihich

Published by Springer International

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U.S. Copyright Law, provided a fee is paid. This fee is US \$ 0.20 per page per copy, plus a basic fee of US \$ 2.00 per article. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäß bei Augsburg

© Springer-Verlag Berlin Heidelberg 1991

Contents of volume 33

No. 1 (pp 1-70) published 11 March 1991
 No. 2 (pp 71-138) published 29 April 1991
 No. 3 (pp 139-202) published 13 May 1991
 No. 4 (pp 203-278) published 20 June 1991
 No. 5 (pp 279-350) published 22 July 1991
 No. 6 (pp 351-424) published 26 August 1991

Andersen V → Vibe-Petersen J
 Anderson TM → Swisher SG
 Arai H → Kurakata S
 Arai M → Kurakata S
 Arita H → Takema M
 Augustus LB → Itoh K

Balazs L → Sharma BS
 Balch CM → Itoh K
 Baldwin RW → Price MR
 Baldwin RW → Mihich E
 Baldwin RW → Demignot S
 Barna BP, Rogers LR, Thomassen MJ,
 Barnett GH, Estes ML: Monocyte
 tumoricidal activity and tumor necrosis
 factor production in patients with malig-
 nant brain tumors 314
 Barnett GH → Barna BP
 Bartholeyns J → Faradji A
 Becker H → Männel DN
 Berger MR, Salas M, Garzon F, Petru E,
 Schwulera U, Schmähli D: Treatment of
 chemically induced autochthonous rat
 mammary and colorectal carcinomas
 with interleukin-2 346

Bergmann L → Weidmann E
 Besana C → Fortis C
 Biffi M → Fortis C
 Blamey RW → Robertson JFR
 Blend MJ → Greager JA
 Bloksma N → Van de Wiel PA
 Blumenthal RD, Fand I, Sharkey RM,
 Boerman OC, Kashi R, Goldenberg
 DM: The effect of antibody protein dose
 of the uniformity of tumor distribution
 of radioantibodies: an autoradiographic
 study 351
 Boerman OC → Blumenthal RD
 Bohbot A → Faradji A
 Braslawsky GR, Kadow K, Knipe J,
 McGoff K, Edson M, Kaneko T, Gren-
 field RS: Adriamycin-hydrazone-anti-
 body conjugates require internalization
 and intracellular acid hydrolysis for
 antitumor activity 367
 Brown JM → Greager JA
 Bucci E → Fortis C
 Busch FW → Pawelec G

Campigotto BMT → Cole SPC
 Chakravarty PK, Sinha DK: Inhibition of
 mammary tumorigenesis in virgin rats by
 adoptive transfer of splenocytes from
 parous donors 263
 Chao T-C → Greager JA
 Chen F-M, Liu C-Z, Epstein AL: Effects of
¹³¹I-labeled TNT-1 radioimmunotherapy
 on HT-29 human colon adenocarcinoma
 spheroids 158
 Chu TM → Nakajima I

Cochran AJ → Swisher SG
 Cohen EP → Nowak J
 Cole SPC, Campigotto BMT, Johnson JG,
 Elliott BE: Differential growth inhibi-
 tion and enhancement of major histo-
 compatibility complex class I antigen
 expression by interferons in a small-cell
 lung cancer cell line and its doxorubicin-
 selected multidrug-resistant variant 274
 Collins JL → Massad LS
 Crum CP → Roche JK

Dalen A → Torp SH
 De Boer EC, De Jong WH, Meijden Van
 der APM, Steerenberg PA, Wijtes JA,
 Vegt PDJ, Debruyne FMJ, Ruitenberg
 EJ: Presence of activated lymphocytes in
 the urine of patients with superficial
 bladder cancer after intravesical immu-
 notherapy with bacillus Calmette-
 Guérin 411
 Debruyne FMJ → De Boer EC
 De Graaf A → Steerenberg PA
 De Jong WH → Steerenberg PA
 De Jong WH → De Boer EC
 Demignot S, Pimm MV, Thorpe SR, Bald-
 win RW: Differences between the cata-
 bolism and tumour distribution of intact
 monoclonal antibody (791T/36) and tis
 Fab/c fragment in mice with tumour
 xenografts revealed by the use of a
 residualizing radiolabel (dilactitol-
¹²⁵I-tyramine) and autoradio-
 graphy 359
 Denkins Y → Utsugi T
 Den Otter W → Steerenberg PA
 Den Otter W → Maas RA
 Diamant M → Vibe-Petersen J
 Dinney CPN → Utsugi T
 Dohlsten M → Lando PA
 Dullens FJ → Maas RA
 Dumont S → Faradji A
 Dunn PL, North RJ: Effect of advanced
 aging on ability of mice to cause regres-
 sion of an immunogenic lymphoma in
 response to immunotherapy based on
 depletion of suppressor T cells 421
 Durrant LG → Price MR
 Dye JF → Somers SS

Eber M → Faradji A
 Edson M → Braslawsky GR
 Eggermont AMM → Kuppen PJK
 Elliott BE → Cole SPC
 Epstein AL → Chen F-M
 Estes ML → Barna BP
 Eura M → Fukui T

Fan D → Utsugi T
 Fand I → Blumenthal RD

Faradji A, Bohbot A, Schmitt-Goguel M,
 Roeslin N, Dumont S, Wiesel M-L, Lal-
 lot C, Eber M, Bartholeyns J, Pointron
 P, Morand G, Witz J-P, Oberling F:
 Phase I trial of intravenous infusion of
 ex-vivo-activated autologous blood-
 derived macrophages in patients with
 non-small-cell lung cancer: toxicity and
 immunomodulatory effects 319
 Fearon E → Itaya T
 Ferrero E → Fortis C
 Fidler IJ → Utsugi T
 Fidler IJ → Utsugi T
 Fiesinger T → Itaya T
 Finkelstein DM, Miller RG: Effect of cul-
 ture media on lymphokine-activated kil-
 ler effector phenotype and lytic capac-
 ity 103
 Fischer P, Störkel S, Haase W, Scherberich
 JE: Differential diagnosis of histogeneti-
 cally distinct human epithelial renal
 tumours with a monoclonal antibody
 against γ -glutamyltransferase 382
 Fleuren GJ → Kuppen PJK
 Fortis C, Ferrero E, Biffi M, Heltai S,
 Besana C, Bucci E, Tresoldi M, Rugarli
 C: Recombinant interleukin-2 and lym-
 phokine-activated killer cells in renal
 cancer patients: II. Characterization of
 cells cultured ex vivo and their contribu-
 tion to the in vivo immunomodula-
 tion 128
 Franz H → Männel DN
 Frost P → Itaya T
 Fuchshuber PR, Lotzová E: Feeder cells
 enhance oncolytic and proliferative
 activity of long-term human bone mar-
 row interleukin-2 cultures and induce
 different lymphocyte subsets 15
 Fukui T, Murakami H, Eura M, Ikawa
 T, Ishikawa T: Killer cells induced by
 stimulation with allogeneic tumor cells
 and subsequent culture with recombi-
 nant interleukin-2 139
 Garzon F → Berger MR
 Geerse E → Steerenberg PA
 Giles FJ → Lim SH
 Goldenberg DM → Blumenthal RD
 Goldstone A → Lim SH
 Goldstone AH → Lim SH
 Golub SH → Swisher SG
 Graf LH Jr → Nowak J
 Greager JA, Chao T-C, Brown JM, Pavel
 DG, Blend MJ, Gupta TKD: Localiza-
 tion of human sarcoma with radio-
 labeled monoclonal antibody - a fol-
 low-up report 341
 Greer JM, Halliday WJ: Effects of anti-
 idotype vaccine on tumour growth and
 on production of soluble factors modu-
 lating cell-mediated immunity in
 vitro 171
 Grenfield RS → Braslawsky GR
 Griesbach A → Schirmacher V
 Guillou PJ → Somers SS
 Gundt A → Männel DN
 Gupta RK → Lindemann RA
 Gupta TKD → Greager JA
 Haase W → Fischer P
 Halliday WJ → Greer JM

- Hara H → Saito S
 Harding MW → Yang T-J
 Harel W → Kan-Mitchell J
 Hashimoto Y → Konno A
 Hayakawa K → Itoh K
 Hayashi S → Saito S
 Hechler P → Weidmann E
 Hedlund G → Lando PA
 Heer E de → Kuppen PJK
 Hellstrom I → Lavie E
 Hellstrom K-E → Lavie E
 Helseth E → Torp SH
 Heltai S → Fortis C
 Hill L → Lavie E
 Hirschberg DL → Lavie E
 Hishinuma A → Kurakata S
 Hishinuma K → Konno A
 Holmes EC → Swisher SG
 Hoogevest P van → Utsugi T
 Hosokawa M → Micallef M
 Hosokawa M → Komatsumoto M
 Howell A → Robertson JFR
 Hunt B → Itaya T
- Ikawa T → Fukiage T
 Imaya H → Matsuura H
 Inaba K → Takema M
 Inoue T → Saito S
 Ishikawa T → Fukiage T
 Itaya T, Fearon E, Fiesinger T, Hunt B, Vogelstein B, Frost P: Immunogenicity of a non-class I MHC expressing murine tumor transfected with the influenza virus hemagglutinin or murine interleukin-2 genes 267
 Itoh K, Hayakawa K, Salmeron MA, Legha SS, Murray JL, Talpaz M, Balch CM, Parkinson DR, Lee K, Zukiwski AA, Ring SE, LaPushin R, Augustus LB: Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy 238
 Itoh K → Mansfield PF
- Jewell A → Lim SH
 Jin A → Sharma BS
 Johnson JG → Cole SPC
 Jolley WB → Sharma BS
- Kadow K → Braslawsky GR
 Kalland T → Lando PA
 Kaneko T → Braslawsky GR
 Kan-Mitchell J, Liggett PE, Harel W, Steinman L, Nitta T, Oksenberg JR, Posner MR, Mitchell MS: Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients 333
 Kao M-S → Massad LS
 Kashi R → Blumenthal RD
 Kassabov KT, Stoychkov JN: Inhibition of spontaneous pulmonary metastases of Lewis lung carcinoma by oral treatment with RespiVax and Broncho-Vaxom 307
 Kawase I → Saito S
 Killion JJ → Utsugi T
 Kimoto Y → Scholz D
 Kimura S → Konno A
 Kishimoto S → Saito S
- Kist A → Männel DN
 Kitamura K → Kurakata S
 Kjerulff AA → Vibe-Petersen J
 Klein E → Wang P
 Klingemann H-G, Wong E: Interleukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cells 395
 Knipe J → Braslawsky GR
 Kobayashi H → Micallef M
 Kobayashi H → Komatsumoto M
 Kobayashi T → Kurakata S
 Kohno H → Kurakata S
 Komatsumoto M, Hosokawa M, Okada F, Okayasu T, Tanabe T, Kobayashi H: The improved effects of specific active immunotherapy on a rat fibrosarcoma by antitumor drugs 279
 Konno A, Hishinuma K, Hashimoto Y, Kimura S, Nishimura T: Dietary restriction reduces the incidence of 3-methylcholanthrene-induced tumors in mice: close correlation with its potentiating effect on host T cell functions 293
 Koprowski H → Scholz D
 Kuppen PJK, Eggermont AMM, Marinelli A, Heer E de, Velde CJH v d, Fleuren GJ: Induction of lymphokine-activated killer activity in rat splenocyte cultures: the importance of 2-mercaptoethanol and indomethacin 28
 Kurakata S, Tomatsu M, Arai M, Arai H, Kohno H, Hishinuma A, Kitamura K, Kobayashi T, Nomoto K: Modulation of the immune response to tumors by a novel synthetic compound, (4R)-3-benzoyl-N-[(1R)-1-phenylethyl]-4-thiazolidinecarboxamide (RS-0481) 71
- Lallot C → Faradji A
 Lando PA, Hedlund G, Dohsten M, Kalland T: Bacterial superantigens as anti-tumour agents: induction of tumour cytotoxicity in human lymphocytes by staphylococcal enterotoxin A 231
 LaPushin R → Itoh K
 Lavie E, Hirschberg DL, Schreiber G, Thor K, Hill L, Hellstrom I, Hellstrom K-E: Monoclonal antibody L6-daunomycin conjugates constructed to release free drug at the lower pH of tumor tissue 223
 Lee K → Itoh K
 Legha SS → Itoh K
 Leidig S → Schirmacher V
 Liggett PE → Kan-Mitchell J
 Lim SH, Worman CP, Goldstone AH: Lymphocyte activation in patients with acute myeloid leukaemia. Evidence for the presence of myeloblast antigen? 417
 Lim SH, Worman CP, Jewell A, Tsakona C, Giles FJ, Goldstone A: Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias 133
 Lindemann RA, Singh KP, Shau H, Gupta RK: The effects of staphylococcal protein A on human lymphokine-activated killer cell induction 97
- Lindvall M, Sjögren HO: Inhibition of rat yolk sac tumour growth in vivo by a monoclonal antibody to the retroviral molecule P15E 21
 Liu C-Z → Chen F-M
 Loibner H → Scholz D
 Lotzová E → Fuchshuber PR
 Lubeck M → Scholz D
- Maas RA, Van Weering DHJ, Dullens FJ, Den Otter W: Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour 389
 Malik GB → Sharma S
 Männel DN, Becker H, Gundt A, Kist A, Franz H: Induction of tumor necrosis factor expression by a lectin from *Viscum album* 177
 Mansfield PF, Rosenblum MG, Murray JL, Itoh K: Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody 247
 Marinelli A → Kuppen PJK
 Massad LS, Mutch DG, Kao M-S, Powell CB, Collins JL: Inhibition of protein synthesis enhances the lytic effects of tumor necrosis factor α and interferon γ in cell lines derived from gynecological malignancies 183
 Masucci G → Wersäll P
 Masuno T → Saito S
 Matsunashi M → Saito S
 Matsuura H, Imaya H: Comparison of lymphokine-activated killer activities between thymocytes and splenocytes in rats with brain tumors 50
 McDonald-Smith J → Scholz D
 McGoff K → Braslawsky GR
 Meijden Van der APM → De Boer EC
 Mellstedt H → Wersäll P
 Micallef M, Hosokawa M, Shibata T, Nakane A, Yang Z-B, Minagawa T, Kobayashi H: Immunoregulatory cytokine release in rat spleen cell cultures after treatment with bleomycin and its analogues in vivo 33
 Mihich E, Baldwin RW: In memory of Professor Yuichi Yamamura (1918-1990) 278
 Miller RG → Finkelstein DM
 Minagawa T → Micallef M
 Mitchell MS → Kan-Mitchell J
 Mitrou PS → Weidmann E
 Möller SA, Reisfeld RA: Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes 210
 Morand G → Faradji A
 Murakami H → Fukiage T
 Muramatsu S → Takema M
 Murray JL → Itoh K
 Murray JL → Mansfield PF
 Mutch DG → Massad LS
- Nakajima I, Chu TM: Synergistic antitumor activity of interleukin-2 and cimetidine against syngeneic murine tumor 9
 Nakamura S → Takema M
 Nakane A → Micallef M

- Nii A → Utsugi T
 Nishimura T → Konno A
 Nitta T → Kan-Mitchell J
 Nomoto K → Kurakata S
 North RJ → Dunn PL
 Nowak J, Cohen EP, Graf LH Jr: Cytotoxic activity toward mouse melanoma following immunization of mice with transfected cells expressing a human melanoma-associated antigen 91
- Oberling F → Faradji A
 Okada F → Komatsumoto M
 Oka S → Takema M
 Okayasu T → Komatsumoto M
 Oksenberg JR → Kan-Mitchell J
 Osaki T → Saito S
 Owsianowsky M → Pawelec G
- Pak CC → Utsugi T
 Palker TJ → Yang T-J
 Parkinson DR → Itoh K
 Pavel DG → Greager JA
 Pawelec G, Reutter M, Owsianowsky M, Rehbein A, Busch FW: Cytotoxic and noncytotoxic mechanisms involved in the *in vitro* anti-leukaemia effects of T cell clones established from a chronic myelogenous leukaemia patient during treatment *in vivo* with interferon α 54
- Pearson D → Robertson JFR
 Pearson J → Robertson JFR
 Petru E → Berger MR
 Phillips NC, Tsao M-S: Liposomal muramyl dipeptide therapy of experimental M5076 liver metastases in mice 85
- Pimm MW → Demignot S
 Poindron P → Faradji A
 Posner MR → Kan-Mitchell J
 Powell CB → Massad LS
 Price MR, Sekowski M, Yang G-Y, Durrant LG, Robins RA, Baldwin RW: Reactivity of an anti-(human gastric carcinoma) monoclonal antibody with core-related peptides of gastrointestinal mucin 80
- Price MR → Robertson JFR
- Ramakrishna V, Shinitzky M: Potentiation of delayed-type hypersensitivity response to syngeneic tumors in mice prevaccinated with cells modified by hydrostatic pressure and crosslinking 1
- Rehbein A → Pawelec G
 Reisfeld RA → Möller SA
 Reutter M → Pawelec G
 Ring SE → Itoh K
 Robertson JFR, Pearson D, Price MR, Selby C, Pearson J, Blamey RW, Howell A: Prospective assessment of the role of five tumour markers in breast cancer 403
- Robins RA → Price MR
 Robins RK → Sharma BS
 Roche JK, Crum CP: Local immunity and the uterine cervix: implications for cancer-associated viruses 203
- Roeslin N → Faradji A
 Rogers LR → Barna BP
 Rosenblum MG → Mansfield PF
- Rugarli C → Fortis C
 Ruitenberg EJ → Steerenberg PA
 Ruitenberg EJ → De Boer EC
- Saha K → Sharma S
 Saito S, Inoue T, Kawase I, Hara H, Tanio Y, Tachibana I, Hayashi S, Watanabe M, Matsunashi M, Osaki T, Masuno T, Kishimoto S: Two monoclonal antibodies against small-cell lung cancer show existence of synergism in binding 165
- Salas M → Berger MR
 Salmeron MA → Itoh K
 Scheper RJ → Steerenberg PA
 Scherberich JE → Fischer P
 Schirmacher V, Leidig S, Griesbach A: *In situ* activation of syngeneic tumour-specific cytotoxic T lymphocytes: Intraperitoneal immunization followed by restimulation in the peritoneal cavity 229
- Schmähel D → Berger MR
 Schmitt-Goguel M → Faradji A
 Scholz D, Lubeck M, Loibner H, McDonald-Smith J, Kimoto Y, Koprowski H, Stepkowski Z: Biological activity in the human system of isotype variants of oligosaccharide-Y-specific murine monoclonal antibodies 153
- Schreiber G → Lavie E
 Schwulera U → Berger MR
 Sekowski M → Price MR
 Selby C → Robertson JFR
 Sharkey RM → Blumenthal RD
 Sharma BS, Balazs L, Jin A, Wang JC-J, Jolley WB, Robins RK: Potentiation of the efficacy of murine L1210 leukemia vaccine by a novel immunostimulator 7-thia-8-oxoguanosine: increased survival after immunization with vaccine plus 7-thia-8-oxoguanosine 109
- Sharma S, Saha K, Shinghal RN, Malik GB: Serum soluble interleukin-2 (IL-2) receptor levels in women with breast carcinoma and its correlation with IL-2 receptor expression on blood lymphocytes and lymphocytic infiltration within the tumour 198
- Shau H → Lindemann RA
 Shibata T → Micallef M
 Shinghal RN → Sharma S
 Shinitzky M → Ramakrishna V
 Singh KP → Lindemann RA
 Sinha DK → Chakravarty PK
 Sjögren HO → Lindvall M
 Sørensen HR → Vibe-Petersen J
 Somers SS, Dye JF, Guillou PJ: Comparison of transforming growth factor β and a human tumour-derived suppressor factor 217
- Steerenberg PA, De Jong WH, Geerse E, De Graaf A, Scheper RJ, Den Otter W, Ruitenberg EJ: Major histocompatibility complex class II antigen expression on leucocyte subpopulations in the draining lymph node and tumour in the early phase of bacillus-Calmette-Guérin-induced tumour regression 189
- Steerenberg PA → De Boer EC
 Steinman L → Kan-Mitchell J
 Stene MA → Swisher SG
 Stepkowski Z → Scholz D
- Störkel S → Fischer P
 Stoychkov JN → Kassabov KT
 Swisher SG, Anderson TM, Wen D-R, Stene MA, Cochran AJ, Golub SH, Holmes EC: Immunopathological features of human pulmonary tumors following low-dose interleukin-2 327
- Tachibana I → Saito S
 Takema M, Oka S, Uno K, Nakamura S, Arita H, Tawara K, Inaba K, Muramatsu S: Macrophage-activating factor extracted from mycoplasmas 39
- Talpaz M → Itoh K
 Tanabe T → Komatsumoto M
 Tanio Y → Saito S
 Tawara K → Takema M
 Thomassen MJ → Barna BP
 Thor K → Lavie E
 Thorpe SR → Demignot S
 Tomatsu M → Kurakata S
 Torp SH, Helseth E, Dalen A, Unsgaard G: Epidermal growth factor receptor expression in human gliomas 61
- Tresoldi M → Fortis C
 Tsakona C → Lim SH
 Tsao M-S → Phillips NC
 Tvede N → Vibe-Petersen J
- Uno K → Takema M
 Unsgaard G → Torp SH
 Utsugi T, Nii A, Fan D, Pak CC, Denkins Y, Hoogevest P van, Fidler IJ: Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages 285
- Utsugi T, Dinney CPN, Killian JJ, Fidler IJ: *In situ* activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31 362 375
- Van der Pijl A → Van de Wiel PA
 Van de Wiel PA, Van der Pijl A, Bloksma N: Role of tumour necrosis factor in the tumour-necrotizing activity of agents with diverging toxicity 115
- Ványk F → Wang P
 Van Weering DHJ → Maas RA
 Vegt PDJ → De Boer EC
 Velde CJH v d → Kuppen PJK
 Vibe-Petersen J, Tvede N, Diamant M, Kjerulff AA, Sørensen HR, Andersen V: Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with non-resectable lung cancer 121
- Vogelstein B → Itaya T
- Wang JC-J → Sharma BS
 Wang P, Ványk F, Klein E: Application of isoelectric focusing for studies of major histocompatibility complex class I antigen expression on human carcinomas and sarcomas 65
- Watanabe M → Saito S
 Weidmann E, Bergmann L, Hechler P, Mitrou PS: Cytotoxic activity and phenotypic characteristics of lymphocyte subsets after therapy of cancer patients with interleukin-2 398

Wen D-R → Swisher SG
Wersäll P, Masucci G, Mellstedt H: Interleukin-4 augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity 45
Wiesel M-L → Faradji A
Witjes JA → De Boer EC
Witz J-P → Faradji A
Wong E → Klingemann H-G

Worman CP → Lim SH
Wright MA → Young MRI
Yang G-Y → Price MR
Yang T-J, Palker TJ, Harding MW: Tumor size, leukocyte adherence inhibition and serum levels of tumor antigen in dogs with the canine transmissible venereal sarcoma 255
Yang Z-B → Micallef M

Young ME → Young MRI
Young MRI, Wright MA, Young ME: Antibodies to colony-stimulating factors block Lewis lung carcinoma cell stimulation of immune-suppressive bone marrow cells 146

Zukiwski AA → Itoh K
Indexed in *Current Contents*

